Literature DB >> 2564330

Why must some schizophrenic patients be involuntarily committed? The role of insight.

J P McEvoy1, P S Applebaum, L J Apperson, J L Geller, S Freter.   

Abstract

Twenty-four of 52 (46%) schizophrenic patients hospitalized because of acute psychotic episodes associated with preadmission medication noncompliance required involuntary commitment. Committed patients were rated as significantly more severely ill than voluntary patients and were significantly more likely to be transferred to extended treatment facilities after acute care. However, committed patients were significantly less likely than were voluntarily admitted patients to acknowledge that they were psychiatrically ill and in need of treatment, i.e., to demonstrate insight. Although psychopathology diminished significantly in both committed and voluntary patients over the course of hospitalization, only in voluntary patients did insight increase significantly. Over a 21/2 to 31/2 year follow-up, those patients who had been involuntarily committed at the index hospitalization were significantly more likely to require involuntary admissions than were the initially voluntary patients. Inability to see the self as ill seems to be a persistent trait in some schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564330     DOI: 10.1016/0010-440x(89)90113-2

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  20 in total

1.  Predictors of clinical and social outcomes following involuntary hospital admission: a prospective observational study.

Authors:  Stefan Priebe; Christina Katsakou; Ksenija Yeeles; Tim Amos; Richard Morriss; Duolao Wang; Til Wykes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-22       Impact factor: 5.270

2.  Clinical encounters with outpatient coercion at the CMHC: questions of implementation and efficacy.

Authors:  J L Geller
Journal:  Community Ment Health J       Date:  1992-04

Review 3.  Lack of insight in schizophrenia: impact on treatment adherence.

Authors:  Peter F Buckley; Donna A Wirshing; Prameet Bhushan; Joseph M Pierre; Seth A Resnick; William C Wirshing
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Treatment compliance in patients with comorbid psychiatric and substance use disorders.

Authors:  Diane M Herbeck; Diana J Fitek; Dace S Svikis; Ivan D Montoya; Steven C Marcus; Joyce C West
Journal:  Am J Addict       Date:  2005 May-Jun

5.  Compliance therapy in psychotic patients: randomised controlled trial.

Authors:  R Kemp; P Hayward; G Applewhaite; B Everitt; A David
Journal:  BMJ       Date:  1996-02-10

6.  Will the new antipsychotics improve the treatment of schizophrenia?

Authors:  T Hale
Journal:  BMJ       Date:  1993-09-25

7.  Rehospitalization risk of former voluntary and involuntary patients with schizophrenia.

Authors:  Carmen Pfiffner; Tilman Steinert; Reinhold Kilian; Thomas Becker; Karel Frasch; Gerhard Eschweiler; Gerhard Längle; Daniela Croissant; Wiltrud Schepp; Prisca Weiser; Susanne Jaeger
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-05-08       Impact factor: 4.328

Review 8.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Outcome of first-episode schizophrenia in India: longitudinal study of effect of insight and psychopathology.

Authors:  Balasubramanian Saravanan; K S Jacob; Shanthi Johnson; Martin Prince; Dinesh Bhugra; Anthony S David
Journal:  Br J Psychiatry       Date:  2010-06       Impact factor: 9.319

10.  Long-term effects of involuntary hospitalization on medication adherence, treatment engagement and perception of coercion.

Authors:  Susanne Jaeger; Carmen Pfiffner; Prisca Weiser; Gerhard Längle; Daniela Croissant; Wiltrud Schepp; Reinhold Kilian; Thomas Becker; Gerhard Eschweiler; Tilman Steinert
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-04-19       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.